Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities



Add a new RSS channel

 

Find news


Tag: analysis


Primary analysis results from Novartis pivotal JULIET trial show Kymriah (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

2017-12-10 16:47:00| PR Newswire: Automotive Industry

EAST HANOVER, N.J., Dec. 10, 2017 /PRNewswire/ -- Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory...

Tags with show results complete

 
Vasyl Lomachenko Vs. Guillermo Rigondeaux Results: Analysis, Social Media Reaction And Purse Info

2017-12-10 05:58:00| Forbes.com News

Vasyl Lomachenko dominates Guillermo Rigondeaux and makes him quit.

Tags info results media social

 
 
Vasyl Lomachenko vs. Guillermo Rigondeaux: Live Blog And Round-by-Round Analysis, Updates

2017-12-10 02:58:00| Forbes.com News

Follow the Vasyl Lomachenko vs. Guillermo Rigondeaux live blog and get round by round analysis, updates, Twitter reaction, results and more before and during the fight.

Tags blog live analysis updates

 
IMBRUVICA (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

2017-12-09 18:03:00| PR Newswire: Automotive Industry

NORTH CHICAGO, Ill., Dec. 9, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced pooled analysis results of the longest follow-up data to date in Bruton's tyrosine kinase (BTK) inhibition for relapsed/refractory (R/R) mantle cell lymphoma (MCL)...

Tags years analysis cell benefit

 
Chopper's Brexit Podcast bonus: Analysis of the Brexit deal

2017-12-08 19:36:09| Telegraph Business

Tags analysis deal bonus podcast

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] next »

Privacy policy . Copyright . Contact form .